252 related articles for article (PubMed ID: 8852905)
1. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection.
King JC; Vink PE; Farley JJ; Smilie M; Parks M; Lichenstein R
Pediatrics; 1997 Apr; 99(4):575-80. PubMed ID: 9093301
[TBL] [Abstract][Full Text] [Related]
3. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age.
King JC; Vink PE; Chang I; Kimura A; Parks M; Smilie M; Lichenstein R; Farley JJ
Vaccine; 1998 Feb; 16(4):361-5. PubMed ID: 9607056
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
5. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
8. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine.
Sorensen RU; Leiva LE; Giangrosso PA; Butler B; Javier FC; Sacerdote DM; Bradford N; Moore C
Pediatr Infect Dis J; 1998 Aug; 17(8):685-91. PubMed ID: 9726341
[TBL] [Abstract][Full Text] [Related]
9. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
[TBL] [Abstract][Full Text] [Related]
10. Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus-Exposed Uninfected Infants: A Randomized Clinical Trial.
Mussi-Pinhata MM; Ward S; Laimon L; Pelton SI; Canniff J; Golner A; Bone F; Newton L; Muresan P; Fenton T; Johnson MJ; João EC; Santos BR; Pilotto JH; Oliveira RH; Pinto JA; Dal Bó AGBL; Kreitchmann R; Chakhtoura N; Duarte G; Weinberg A
Clin Infect Dis; 2022 Sep; 75(6):996-1005. PubMed ID: 35037049
[TBL] [Abstract][Full Text] [Related]
11. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.
Crum-Cianflone NF; Huppler Hullsiek K; Roediger M; Ganesan A; Patel S; Landrum ML; Weintrob A; Agan BK; Medina S; Rahkola J; Hale BR; Janoff EN;
J Infect Dis; 2010 Oct; 202(7):1114-25. PubMed ID: 20795819
[TBL] [Abstract][Full Text] [Related]
13. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
Nachman S; Kim S; King J; Abrams EJ; Margolis D; Petru A; Shearer W; Smith E; Moye J; Blanchard S; Hawkins E; Bouquin P; Vink P; Benson M; Estep S; Malinoski F;
Pediatrics; 2003 Jul; 112(1 Pt 1):66-73. PubMed ID: 12837869
[TBL] [Abstract][Full Text] [Related]
15. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
[TBL] [Abstract][Full Text] [Related]
16. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.
Rose MA; Schubert R; Strnad N; Zielen S
Clin Diagn Lab Immunol; 2005 Oct; 12(10):1216-22. PubMed ID: 16210486
[TBL] [Abstract][Full Text] [Related]
17. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.
Abzug MJ; Song LY; Levin MJ; Nachman SA; Borkowsky W; Pelton SI;
Vaccine; 2013 Oct; 31(42):4782-90. PubMed ID: 23954381
[TBL] [Abstract][Full Text] [Related]
18. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.
Ohtola JA; Khaskhely NM; Saul-Mcbeth JL; Iyer AS; Leggat DJ; Khuder SA; Westerink MAJ
Vaccine; 2016 Jan; 34(4):451-457. PubMed ID: 26707220
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children.
Madhi SA; Kuwanda L; Cutland C; Holm A; Käyhty H; Klugman KP
Pediatr Infect Dis J; 2005 May; 24(5):410-6. PubMed ID: 15876939
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
